APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board
with a view to the strategic development of the Company

EQS-News: APONTIS PHARMA AG / Key word(s): Personnel
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board
with a view to the strategic development of the Company

27.06.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board
with a view to the strategic development of the Company

Monheim / Rhein, 27 June 2024. APONTIS PHARMA AG (Ticker APPH / ISIN
DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pill
combinations in the German market, expands its Executive Board with a view
to the Company's strategic development. To reflect the growing portfolio of
single pill combinations, the future internationalization of the Company and
the upcoming further development of the ESG strategy, the Finance department
within the Executive Board will be strengthened. With effect from 1 July
2024, the Supervisory Board appointed CFO Thomas Zimmermann to the Executive
Board with a contract term until 30 June 2027.

Thomas Zimmermann has been CFO of the APONTIS PHARMA Group since 1 January
2022. Since then, he has further developed the finance department and played
a key role in the realignment of the company from September 2023. He will
strengthen the Executive Board team sustainably and be responsible for
Finance, Investor Relations, Compliance, Contract Management, IT and ESG.

Dr. Matthias Wiedenfels, Chairman of the Supervisory Board of APONTIS PHARMA
AG: 'Thomas Zimmermann is a proven financial expert with strong
pharmaceutical expertise and is very familiar with the corporate processes
of APONTIS PHARMA. He has played a decisive role in shaping the realignment
of the Company. With the increasing number of Single Pill combinations, the
future internationalization of the Company and the strengthening of our
positive contribution to ESG, we are pleased to establish a strong finance
department at Management Board level.'

Thomas Zimmermann, designated member of the Executive Board of APONTIS
PHARMA AG: 'I am very honored about the trust placed in me and the
opportunity to drive the further development of APONTIS PHARMA together with
Bruno Wohlschlegel and Thomas Milz as well as the entire team. In doing so,
I will continue to focus on efficient and lean processes and expand this to
include effective risk and contract management in preparation of the future
internationalization.'

Additional information:

Information on upcoming events can be found at
https://apontis-pharma.de/en/financial-calendar and the latest analyst
assessments at https://apontis-pharma.de/en/share-price.

About APONTIS PHARMA:

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single
Pill combinations in Germany. Single Pills combine two to three generic
active ingredients in a single dosage form administered once a day. Single
Pill therapies have been scientifically proven to significantly increase
adherence and thus improve the treatment prognosis and quality of life of
patients while reducing complications, mortality, and treatment costs.
Consequently, Single Pill combinations are the preferred treatment option in
numerous international treatment guidelines, including in the EU and
Germany. APONTIS PHARMA has been developing, promoting, and distributing a
broad portfolio of Single Pill combinations and other pharmaceutical
products since 2013, with a special focus on cardiovascular diseases such as
hypertension, hyperlipidemia, and secondary prevention. For additional
information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Alfred-Nobel-Str. 10
40789 Monheim / Rhein
Germany
apontis-pharma.de

APONTIS PHARMA Press Contact

CROSS ALLIANCE communication GmbH
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330


---------------------------------------------------------------------------

27.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        APONTIS PHARMA AG
                   Rolf-Schwarz-Schütte-Platz 1
                   40789 Monheim am Rhein
                   Germany
   E-mail:         ir@apontis-pharma.de
   Internet:       https://apontis-pharma.de/
   ISIN:           DE000A3CMGM5
   WKN:            A3CMGM
   Listed:         Regulated Unofficial Market in Berlin, Dusseldorf,
                   Frankfurt (Scale), Munich, Stuttgart, Tradegate
                   Exchange
   EQS News ID:    1931745

End of News EQS News Service
---------------------------------------------------------------------------

1931745 27.06.2024 CET/CEST